Halozyme Provides Update on German Preliminary Injunction Hearing
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Halozyme Therapeutics (HALO) reported that Germany’s Higher Regional Court overturned the preliminary injunction barring Merck from distributing and offering Keytruda SC in Germany. The original order was issued in December 2025.
Separately, in October 2026, a Dutch patent court restricted Merck’s European marketing approval holder from specified Keytruda SC activities in eight countries. The MDASE patents at issue are outside Halozyme’s ENHANZE licensing program and distinct from its ENHANZE patents. Halozyme said the outcome of its MDASE patent enforcement against Merck will not affect licensees’ ability to use ENHANZE or the revenue Halozyme receives from them.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointDutch court order restricts Merck’s European marketing approval holder from specified Keytruda SC activities in eight countries.
- Minor point. Forward-looking: it has not happened yet and may not happen.ENHANZE licensing revenue will not be affected by the MDASE patent enforcement outcome, Halozyme said.
Negative
- Moderate pointGerman preliminary injunction overturned, lifting the order barring Merck from distributing and offering Keytruda SC in Germany.
News Explained
After the German court overturned the preliminary injunction, Halozyme says it will immediately file an infringement lawsuit against Merck seeking permanent relief; the court’s decision does not preclude that suit.
Historical Context
-
Dutch ruling restricted Merck in eight European markets; the German injunction was separately overturned.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hyaluronidases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
"We are disappointed that the Higher Regional Court overturned the preliminary injunction halting the launch of Keytruda SC in
Separately and independently, in October 2026, a Dutch patent court prohibited Merck's European Marketing Approval holder from committing an infringement in
The patents at issue arise from Halozyme's extensive research into nearly 7,000 modifications to human hyaluronidases. Among their uses, these hyaluronidases pioneered by Halozyme provide a mechanism for the rapid SC administration of therapeutic drugs. Halozyme's comprehensive studies and innovations were a significant advancement to the field of human-derived hyaluronidases.
The MDASE™ patents are not included in Halozyme's ENHANZE® licensing program and are distinct from its ENHANZE® patents. Therefore, the outcome of the global enforcement of its MDASE™ patents against Merck will not impact ENHANZE®, the ability of any licensee to use ENHANZE®, or revenues Halozyme receives from ENHANZE® licensees.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is microparticle technology with the potential to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Aerocon™ polymer-based hyperconcentration technology may further broaden the range of biologics that can be delivered subcutaneously. Together, we believe Hypercon™ and Aerocon™ technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of Halozyme's ENHANZE® and MDASE™ drug delivery technologies, the possible method of action of these technologies, their potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of these technologies including facilitating more rapid delivery of high-volume injectable medications through subcutaneous delivery. These forward-looking statements also include statements with respect to the decision of the Munich Higher Regional Court to overturn the Munich Regional Court's decision to issue a preliminary injunction halting the launch of Keytruda SC in Germany, Halozyme's plans to file an infringement lawsuit against Merck in Germany, the decision of a Dutch court prohibiting Merck's European Marketing Approval holder from committing infringement in various European countries and statements with respect to the strength and validity of Halozyme's intellectual property. These forward-looking statements also include statements with respect to Halozyme's global enforcement of its MDASE™ patents against infringement by Merck's Keytruda SC to enforce Halozyme's patent rights, including Halozyme's allegation that Merck's Keytruda SC infringes multiple Halozyme patents and Halozyme's belief that the outcome of its global enforcement of its MDASE™ patents against Merck will not impact its ENHANZE® licensing program or the revenues Halozyme receives from ENHANZE® licensees. These forward-looking statements involve risks and uncertainties beyond Halozyme's control that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors and Halozyme can offer no assurance with respect to such forward-looking statements and cautions the reader not to place undue reliance on these forward-looking statements. In particular, there can be no assurance as to developments related to the litigation and other legal proceedings related to Halozyme's global enforcement of its MDASE™ patents against infringement by Merck's Keytruda SC referred to in this press release, the outcome of these legal proceedings or any remedies that could be awarded in connection with the legal proceedings. Actual results could also differ materially from expectations contained in this press release as a result of other risks and uncertainties including those related to future decisions by the courts in Germany or by Dutch courts with respect to the decision of a Dutch court referred to in this press release or the strength, enforceability and validity of Halozyme's patents, future revenues and the cost of litigation. These and other factors that may result in material differences from the forward-looking statements contained in this press release are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contact:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-provides-update-on-german-preliminary-injunction-hearing-302945598.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.